Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

Samer A. Srour, Rima M. Saliba, Maria C.B. Bittencourt, Jorge M.R. Perez, Piyanuch Kongtim, Amin Alousi, Gheath Al-Atrash, Amanda Olson, Oran Betul, Rohtesh Mehta, Uday Popat, Chitra Hosing, Qaiser Bashir, Issa Khouri, Partow Kebriaei, Lucia Masarova, Nicholas Short, Elias Jabbour, Naval Daver, Marina KonoplevaFarhad Ravandi, Hagop Kantarjian, Richard E. Champlin, Stefan O. Ciurea

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

There have been conflicting results regarding the impact of minimal/measurable disease at transplant on acute myeloid leukemia (AML) outcomes after haploidentical transplantation (haplo-SCT). We assessed the impact of pre-transplant disease status on post-transplant outcomes of 143 patients treated with haplo-SCT using fludarabine-melphalan (FM) conditioning and post-transplant cyclophosphamide (PTCy). With a median follow-up of 29 months, the two-year PFS for all patients was 41%. Compared to patients in complete remission (CR) at transplant, those with active disease (n = 29) and CR with incomplete count recovery (CRi) (n = 39) had worse PFS. They had hazard ratios (HR) of 3.5 (95% CI: 2.05-6.1; P <.001) and 2.3 (95% CI: 1.3-3.9; P =.002), respectively. Among patients who were in CR at transplant, there were no differences in PFS between those who had minimal residual disease (MRD) positive (n = 24), and MRD negative (n = 41) (HR 1.85, 95%CI: 0.9-4.0; P =.1). In multivariable analysis for patients in CR, only age was predictive for outcomes, while MRD status at transplant did not influence the treatment outcomes. Our findings suggest that haplo-SCT with FM conditioning regimen and PTCy-based GVHD prophylaxis has a protective effect, and may potentially abrogate the inferior outcomes of MRD positivity for patients with AML. Patients with positive MRD may benefit from proceeding urgently to a haplo-SCT, as this does not appear to negatively impact transplant outcomes.

Original languageEnglish (US)
Pages (from-to)1382-1387
Number of pages6
JournalAmerican journal of hematology
Volume94
Issue number12
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Hematology

MD Anderson CCSG core facilities

  • Clinical Trials Office

Fingerprint

Dive into the research topics of 'Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation'. Together they form a unique fingerprint.

Cite this